Clinical Trial Update: A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine [Phase 1]

View source ↗

Summary

Phase I randomized, open-label, cross-over pharmacokinetic study evaluating Genasense with and without Dacarbazine in advanced melanoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Genasense (oblimersen)

Snippet

Sponsor: Genta Incorporated | Conditions: Advanced Melanoma | Phase 1 | Status: COMPLETED